SW · NOVN.SW · DRUG MANUFACTURERS - GENERAL
Novartis AG (NOVN.SW) intrinsic value and stock valuation
$127.76as of 2026-11-21 · Mkt cap 226.76B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Novartis AG DCF and intrinsic value
InvestorsCraft values NOVN.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NOVN.SW’s statements →
Novartis AG Graham Number
Graham Number: $63.86d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $57.1B | $51.7B | $46.7B | $43.5B | $44B |
| Operating income | $17.8B | $14.5B | $9.77B | $7.95B | $10.1B |
| Net income | $14.6B | $11.9B | $14.9B | $6.96B | $24B |
| EPSd | $7.49M | $5.87M | $7.1M | $3.17M | $10.6M |
| Operating cash flow | $20.1B | $17.6B | $14.5B | $14.2B | $15.1B |
| Capital expenditure | -$-1.62B | -$-3.81B | -$-2.75B | -$-2.67B | -$-2.97B |
| Free cash flow | $18.4B | $13.8B | $11.7B | $11.6B | $12.1B |
| Total assets | $115.5B | $102.2B | $99.9B | $117.5B | $131.8B |
| Total debt | $37B | $31.3B | $26.3B | $27.9B | $31B |
| Net debt | $25.6B | $19.8B | $13B | $20.4B | $18.6B |
| Total equity | $46.5B | $44.1B | $46.8B | $59.4B | $67.8B |
| Cash and short-term investments | $11.6B | $13.4B | $14B | $18.6B | $28.1B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $57.1B | $51.7B | $46.7B | $43.5B | $44B |
| Cost of revenue | $14.3B | $12.8B | $12.5B | $11.6B | $11.7B |
| Gross profit | $42.9B | $38.9B | $34.2B | $31.9B | $32.2B |
| Research and development expenses | $11.2B | $10B | $11.4B | $9.17B | $8.64B |
| Selling, general and administrative expenses | $13.9B | $12.6B | $12.5B | $12.2B | $12.8B |
| Other expenses | $0.00 | $1.76B | $531M | $2.57B | $715M |
| Operating expenses | $25.1B | $24.4B | $24.4B | $23.9B | $22.2B |
| Cost and expenses | $39.3B | $37.2B | $36.9B | $35.5B | $33.9B |
| Interest income | $390.8M | $550.8M | $658.5M | $389.3M | $71M |
| Interest expense | $1.24B | $1.01B | $916.9M | $860.2M | $904.8M |
| Depreciation and amortization | $5.58B | $6.07B | $8.28B | $6.71B | $5.6B |
| Ebitda | $24B | $20.7B | $18.3B | $14.7B | $30.9B |
| Operating income | $17.8B | $14.5B | $9.77B | $7.95B | $10.1B |
| Total other income/expenses, net | -$-665.21M | -$-904M | -$-646M | -$-769M | $14.5B |
| Income before tax | $17.1B | $13.6B | $9.12B | $7.18B | $24.5B |
| Income tax expense | $2.5B | $1.7B | $551M | $1.13B | $1.63B |
| Net income | $14.6B | $11.9B | $14.9B | $6.96B | $24B |
| Weighted average shares outstanding | $1.94B | $2.02B | $2.09B | $2.18B | $2.24B |
| Weighted average diluted shares outstanding | $1.96B | $2.04B | $2.09B | $2.2B | $2.26B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $11.6B | $13.4B | $14B | $18.6B | $28.1B |
| Net receivables | $10.9B | $9.54B | $9.38B | $9.89B | $9.62B |
| Inventory | $6.26B | $5.72B | $5.91B | $7.18B | $6.67B |
| Total current assets | $30.4B | $29.7B | $30.5B | $36.9B | $45.7B |
| Property, plant and equipment, net | $12.3B | $10.9B | $10.9B | $12.2B | $13.1B |
| Goodwill and intangible assets | $54.9B | $51.7B | $50.2B | $60.9B | $63.8B |
| Long-term investments | $2.3B | $1.13B | $1.83B | $1.61B | $2.27B |
| Total non-current assets | $85.1B | $72.5B | $69.5B | $80.5B | $86.1B |
| Total assets | $115.5B | $102.2B | $99.9B | $117.5B | $131.8B |
| Accounts payable | $4.45B | $4.57B | $4.93B | $5.15B | $5.55B |
| Short-term debt | $5.78B | $8.32B | $6.31B | $6.13B | $6.5B |
| Deferred revenue | $0.00 | $127M | $98M | $123M | $123M |
| Total current liabilities | $27.3B | $28.7B | $26.4B | $28.7B | $30.2B |
| Long-term debt | $31.2B | $22.9B | $20B | $21.8B | $24.5B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $41.7B | $29.4B | $26.8B | $29.4B | $33.8B |
| Capital lease obligations | $1.92B | $1.8B | $1.83B | $1.79B | $1.9B |
| Total liabilities | $69B | $58.1B | $53.2B | $58B | $64B |
| Common stock | $765.5M | $793M | $825M | $890M | $901M |
| Retained earnings | $44.7B | $46.6B | $49.6B | $63.5B | $71B |
| Accumulated other comprehensive income (loss) | $693.5M | -$-3.25B | -$-3.7B | -$-5B | -$-4.17B |
| Total equity | $46.5B | $44.1B | $46.8B | $59.4B | $67.8B |
| Total investments | $2.46B | $3.02B | $2.4B | $12.7B | $18B |
| Total debt | $37B | $31.3B | $26.3B | $27.9B | $31B |
| Net debt | $25.6B | $19.8B | $13B | $20.4B | $18.6B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $14.6B | $11.9B | $8.57B | $6.96B | $24B |
| Depreciation and amortization | $5.58B | $6.07B | $8.28B | $7.18B | $6.11B |
| Stock-based compensation | $0.00 | $1.04B | $865M | $791M | $700M |
| Change in working capital | -$-3.21B | -$-706M | -$-369M | -$-1B | $241M |
| Accounts receivable | -$-1.18B | -$-931M | -$-1.5B | -$-589M | -$-389M |
| Inventory | $35.6M | -$-225M | -$-546M | -$-830M | $81M |
| Accounts payable | -$-285.99M | -$-105M | $479M | -$-48M | -$-21M |
| Net cash provided by operating activities | $20.1B | $17.6B | $14.5B | $14.2B | $15.1B |
| Investments in property, plant and equipment | -$-4.09B | -$-1.37B | -$-1.06B | -$-2.67B | -$-2.97B |
| Acquisitions, net | -$-3.13B | -$-3.92B | -$-3.56B | -$-903M | $20.1B |
| Net cash used for investing activities | -$-5.11B | -$-7.51B | $5.6B | $1.47B | $4.21B |
| Common stock issued | $28.3M | $0.00 | $0.00 | $0.00 | $53M |
| Common stock repurchased | -$-9.65B | -$-8.33B | -$-8.72B | -$-10.65B | -$-3.06B |
| Dividends paid | -$-8.19B | -$-7.62B | -$-7.26B | -$-7.51B | -$-7.37B |
| Net cash used for financing activities | -$-15.57B | -$-11.74B | -$-14.28B | -$-20.56B | -$-16.26B |
| Net change in cash | -$-1.67B | -$-1.93B | $5.88B | -$-4.89B | $2.75B |
| Cash at end of period | $11.4B | $11.5B | $13.4B | $7.52B | $12.4B |
| Operating cash flow | $20.1B | $17.6B | $14.5B | $14.2B | $15.1B |
| Capital expenditure | -$-1.62B | -$-3.81B | -$-2.75B | -$-2.67B | -$-2.97B |
| Free cash flow | $18.4B | $13.8B | $11.7B | $11.6B | $12.1B |
Line items
Line items
Line items
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
- CEO
- Vasant Narasimhan
- Employees
- 75.88K
- Beta
- 0.49
Included in
Explore
Frequently asked questions
What is the intrinsic value of Novartis AG (NOVN.SW)?
InvestorsCraft does not currently publish an intrinsic value for NOVN.SW. How the IC value is calculated.
Is NOVN.SW undervalued?
InvestorsCraft does not publish an undervaluation signal for NOVN.SW at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.